In vitro susceptibility of 100 clinical isolates of Neisseria gonorrhoeae to trimethoprim-sulfamethoxazole (TMP-SMZ combination; 1:19) was deternined by the agar dilution technique using three different media under similar conditions. On Oxoid diagnostic sensitivity test, Mueller-Hinton, and GC agar media, the percentage of isolates inhibited by 2.5 ug or less ofTMP per ml and 47.5 ,ug or less of SMZ per ml were 95, 90, and 84%, respectively. TMP-SMZ appeared to be effective in vitro against N. gonorrhoeae despite differences in the types of media used.
In vitro susceptibility of 100 clinical isolates of Neisseria gonorrhoeae to trimethoprim-sulfamethoxazole (TMP-SMZ combination; 1:19) was deternined by the agar dilution technique using three different media under similar conditions. On Oxoid diagnostic sensitivity test, Mueller-Hinton, and GC agar media, the percentage of isolates inhibited by 2.5 ug or less ofTMP per ml and 47.5 ,ug or less of SMZ per ml were 95, 90, and 84%, respectively. TMP-SMZ appeared to be effective in vitro against N. gonorrhoeae despite differences in the types of media used.
Gonorrhea is presently a major infectious disease problem. The increased frequency of penicillin-resistant strains of Neisseria gonorrhoeae in uncomplicated infection (9, 16, 19) has made it imperative that clinicians seek other effective chemotherapeutic agents. Although tetracycline is effective in eradicating anogenital gonorrhea, resistance to this antibiotic is becoming increasingly apparent (2, 12) . Similarly, spectinomycin-resistant strains ofN. gonorrhoeae have been isolated (12, 17) . Moreover, cross-resistance to multiple antibiotics, including penicillin, tetracycline, spectinomycin, chloramphenicol, and erythromycin, is now being reported (10, 12, 15) .
Trimethoprim (2,4-diamino-5[3,4,5-trimethoxybenzyl]pyrimidine; TMP) in combination with a sulfonamide has demonstrated in vitro synergism in inhibiting growth of a variety of gramnegative bacillary organisms (1, 4, 7) . Although preliminary in vitro data suggested that TMP plus sulfamethoxazole (SMZ) was also effective against N. gonorrhoeae (4, 7, 8, 13) , a wide variety of media and conditions were used to obtain this information. The fastidious nature of the gonococcal organism, and the potential interaction of various media constituents with TMP-SMZ, make it imperative that a standardized method be utilized to meaningfully evaluate the efficacy of this agent against this bacterium. To investigate this problem, the in vitro susceptibility of 100 clinical isolates ofN. gonorrhoeae to TMP-SMZ, in a combination of one part TMP and 19 parts SMZ, was determined on three different media under similar conditions, using an agar dilution technique. and GC agars (BBL, GC agar base) were freshly prepared and enriched with 1% IsoVitaleX (BBL). Five-percent lysed horse blood (Scott Lab., Fiskeville, R.I.) was incorporated into each medium. The horse blood was lysed by the addition of 1:50 of a 10% saponin solution (7) . Serial twofold dilutions of TMP and SMZ (provided by Hoffman LaRoche, Inc.) in a 1:19 combination starting with 5 ,ug of TMP per ml and 95 ug of SMZ per ml were prepared and incorporated into each medium. Susceptibility testing. Susceptibility ofN. gonorrhoeae to TMP-SMZ was determined by an agar dilution technique previously described (22 gonorrhoeae to TMP-SMZ, in vitro susceptibility studies were performed using three different media concurrently under similar conditions. Oxoid DST agar was selected because of its low thymidine content (7); Mueller-Hinton and GC agars were chosen because of their frequent use for susceptibility studies of other antibiotics against N. gonorrhoeae (2, 14, 22). All media were enriched with 1% IsoVitaleX and prepared with 5% lysed horse blood to inactivate thymidine (to thymine) which may interfere with action of TMP and SMZ (7) . TMP and SMZ were incorporated into the media at a 1:19 ratio. Based on in vivo pharmacokinetic studies (11) , this approximates the blood-level ratio of the two compounds when ingested in the commercially available form of one part TMP to five parts SMZ. Inoculum size was kept uniforn utilizing a Steers replicating apparatus, and all plates were read at 24 h.
With utilization of a uniforn methodology, the in vitro susceptibility of 100 gonococcal isolates to TMP-SMZ was relatively similar on all three media. The percentage of organisms with MICs to TMP (as TMP-SMZ) in the range of 0.16 to 2.5 ug/ml to Oxoid DST, Mueller-Hinton, and GC media were 95, 90, and 84%, respectively. This is not dissimilar from previously reported susceptibility data for N. gonorrhoeae against TMP (as TMP-SMZ) (4, 7) . These MIC values are well within the range of achievable blood levels of TMP previously reported after ingestion of TMP (as TMP-SMZ in 1:5 ratio) in single doses of 240 and 400 mg (6, 11) . Additionally, the peak blood levels of SMZ in these studies were between 50 and 60 ,ug/ml at the time serum concentrations of TMP were 2.5 to 3.0 Fg/ml. Therefore, the concentrations ofboth TMP and SMZ required for inhibition of most strains ofN. gonorrhoeae can be easily achievable in the blood.
It would appear then that, with a uniformly standardized methodology, the in vitro susceptibility data of this organism to TMP-SMZ are comparable despite differences in types of media used. However, with GC agar the control organisms, S. aureus, E. coil, and S. faecalis, were not completely inhibited at concentrations up to 5 to 95 ,ug/ml of TMP-SMZ; usually one to two colonies were still visible. Furthermore, the slightly greater number of gonococcal isolates on GC agar (as compared to DST or Mueller-Hinton) with TMP-SMZ concentrations of 5 to 95 ,ug/ml or higher may suggest that this medium may be less desirable than the other two. 
